Biosimilars in the Canadian market
Before they can be approved by Health Canada, biosimilars have to go though an extremely thorough authorization process based on how similar they are to their reference biologic drug. Showing this similarity involves many steps, beginning with structural and functional studies, and moving on to human studies. Teva Canada is committed to making sure that any biosimilar we manufacture is made in state-of-the-art facilities with the highest-quality agents.
Regulatory pathways of originator biologics vs. biosimilars
 |
As biosimilars continue to grow in importance within the Canadian market, they are predicted to contribute to the sustainability of the healthcare system via:
Reduced cost
Biosimilars typically cost less than their reference biologics.
Increased competition
Biosimilars introduce competition, which in turn may also help reduce costs.
Improved drug accessibility
Savings from biosimilars could be put towards funding for other much-needed therapeutic areas.
